Telomir Pharmaceuticals, Inc. - Common Stock (TELO)
4.1300
0.00 (0.00%)
Telomir Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies that target cellular aging and age-related diseases
The company specializes in the research and development of medications aimed at enhancing telomere function, which plays a crucial role in cellular health and longevity. By leveraging advanced scientific insights, Telomir Pharmaceuticals aims to transform the treatment landscape for conditions such as cancer and degenerative diseases, ultimately striving to improve the quality of life for patients by addressing the underlying mechanisms of aging.
Telomir Pharmaceuticals' Telomir-1 stabilizes Silver(II) for medical use, addressing instability issues in antimicrobial treatments and wound care solutions.
Telomir-1 shows potential as a treatment for Wilson's disease and related disorders, with promising preclinical results and potential for orphan drug designation.
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation
Shares of AppLovin Corporation (NASDAQAPP) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a drug developer this year.
